Similar articles

• Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.

  Kiriyama T, Kataoka H, Taoka T, Tonomura Y, Terashima M, Morikawa M, Tanizawa E, Kawahara M, Furiya Y, Sugie K, Kichikawa K, Ueno S. Kiriyama T, et al. J Neuroimaging. 2011 Apr;21(2):e69-77. doi: 10.1111/j.1552-6569.2010.00502.x. J Neuroimaging. 2011. PMID: 20572907
• Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal.

  Dastgir J, DiMario FJ Jr. Dastgir J, et al. J Child Neurol. 2009 Apr;24(4):431-7. doi: 10.1177/0883073808324769. Epub 2009 Feb 2. J Child Neurol. 2009. PMID: 19189932
• Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.

  Malhotra HS, Jain KK, Agarwal A, Singh MK, Yadav SK, Husain M, Krishnani N, Gupta RK. Malhotra HS, et al. Mult Scler. 2009 Feb;15(2):193-203. doi: 10.1177/1352458508097922. Mult Scler. 2009. PMID: 19181773
• [Handicap lesions: recent contributions of imaging and neuropathology].

  Brochet B. Brochet B. Rev Neurol (Paris). 2008 Apr;164 Spec No 2:F131-7. Rev Neurol (Paris). 2008. PMID: 18680831 Review. French. No abstract available.
• Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group.

  Filippi M, Falini A, Arnold DL, Fazekas F, Gonen O, Simon JH, Dousset V, Savoiardo M, Wolinsky JS; White Matter Study Group. Filippi M, et al. J Magn Reson Imaging. 2005 Jun;21(6):669-75. doi: 10.1002/jmri.20336. J Magn Reson Imaging. 2005. PMID: 15906322 Review.